The PI3K/AKT/mTOR pathway has become a “hot spot” of molecular biomarker-based/targeted therapy because research in several types of cancer, such as breast, liver, colorectal, prostate, and gastric cancers, shows the presence of irregularities in this pathway [211]. This evidence concerns the gene MTOR and gastric cancer.